CHICAGO Nov 10 CVS Caremark Corp (CVS.N) said
on Tuesday it would start offering pharmacy benefit management
clients more genetic services next year under a deal with
Generation Health Inc, in which it is taking a minority stake.
The deal with privately held Generation Health will expand
pharmacogenomic clinical and testing services.
Such services can help doctors evaluate a patient's genetic
make-up to determine if a medication will be effective and
should help improve care for patients who do not respond to or
have adverse reactions to their medication, CVS said.
CVS Caremark's pharmacy benefits management business, or
PBM, administers prescription drug benefits for employers and
health plans and operates a large mail-order pharmacy.
Last week, CVS stunned investors when it said that its PBM
had lost $4.8 billion in business heading into next year.
CVS Caremark already provides pharmacogenomic intervention
services in its specialty pharmacy business. Now, under the new
partnership, it plans to introduce those services for certain
drugs dispensed under the traditional PBM.
The companies said they would first focus on clinical and
testing programs that predict how a patient will respond to
medications in areas such as oncology, cardiovascular medicine
and the treatment of HIV.
The services are set to be introduced to CVS Caremark's PBM
clients in the second quarter of 2010.
As part of the deal, CVS Chief Medical Officer Dr. Troyen
Brennan will join Generation Health's board of directors.
Generation Health was created in November 2008 with funding
from its founders and venture capital firm Highland Capital
(Reporting by Jessica Wohl, editing by Maureen Bavdek)